




RealRate

PHARMACEUTICAL 2022

Effector Therapeutics Inc
Rank 296 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Effector Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Effector Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Effector Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 153% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 31% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	52,896
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,978
Liabilities, Non-Current	126
Other Assets	1,069
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	32,668
Other Net Income	47,695
Other Revenues	1,430
Property and Equipment	91
Research and Development	19,956
Selling, General and Administrative Expense	13,371

Output Variable	Value in 1000 USD
Assets	54,056
Liabilities	36,772
Expenses	33,327
Revenues	1,430
Stockholders Equity	17,284
Net Income	15,798
Comprehensive Net Income	15,798
BaseVar	86,640
ECR before Limited Liability	118%
Economic Capital Ratio	244%